…required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire Download available on Google Chrome, Internet Explorer, Safari, Firefox and Edge. Should you experience technical difficulties in downloading the PowerPoint file, please email us:at i…
…lt Scler Relat Disord 2017;18:141-143) or worsening inflammatory activity with biotin (Granella et al. ECTRIMS 2017; abstract P750). Additional studies will be required. SPMS Part 2 – Survey Complete the survey on your experience with SPMS. All responses will appear once you complete the survey and click Submit. This poll is currently disabled….
…incidence rate for all-cause mortality was two-fold higher in MS patients compared to the general population (Persson et al. EAN 2019; abstract O1206). The most common cause of death was pneumonia; the incidence of cancer deaths was not elevated in MS patients. Sustained NEDA with cladribine: In the CLARITY study, 47% of patients treated with cladribine 3.5 mg/kg achieved no evidence of disease activity (NEDA) at 96 weeks (Giovannoni et al. Lance…
Here are Steven’s Poster Picks for Monday, May 6, 2019: Migraine Long-term data for frenezumab (P2.10-002, P2.10-008, P2.10-015) and galcanezumab (P2.10-010) Safety of ubrogepant (P2.10-003, P2.10-009) Parkinson’s disease Levodopa inhalation powder (P2.8-048): sublingual apomorphine (P2.8-053) Suicidal behaviour (P2.8-025) Multiple sclerosis – Basic science Bruton’s tyrosine kinase inhibition (P2.2-063, P2.2-077) Myelin-reactive CD8+ T cells (P2….
…shed March 12, 2019; free full text at https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1002/prp2.470). Nilotinib (Tasigna) is a small-molecule TKI that targets breakpoint cluster/Abelson (BCR-Abl) and is approved to treat chronic myelogenous leukemia (CML) at a dose of 300-400 mg BID. Other agents in this class include imatinib (Gleevec), ponatinib (Iclusig) and bafetinib (INNO-406, a BCR-Abl/Lyn TKI). In the CNS, c-Abl regulates neurogenesis,…